ESMO Lung Cancer 2022 – Gérard Zalcman

Gérard Zalcman discusses recent findings regarding the duration of immune checkpoint inhibitor treatment in patients with NSCLC, expectations of checkpoint inhibitor therapy in the setting of unresectable malignant pleural mesothelioma and how the treatment of patients with malignant pleural mesothelioma might be further optimized based on molecular findings.

Here is the full ESMO 2022 Solid Tumors report.

More posts

Promising therapeutic strategies for colorectal cancer treatment

With more than 1.9 million new cases, colorectal cancer (CRC) accounted in 2020 for 10 % of all diagnosed cancers. CRC ranked third in terms of incidence and was the second leading cause of cancer mortality worldwide, with 935,000 estimated deaths in 2020. Over the last five years, clinical studies have shown that treatments specifically tailored to the molecular and pathological characteristics of the tumor improved overall survival.

From neoadjuvant to second-line therapeutic options for RCC patients

Kidney cancer accounted for more than 400,000 newly diagnosed cases in 2020,. Interestingly, after over two decades of increasing rates, the worldwide incidence of renal cell carcinoma (RCC) has shown signs of plateauing in recent years, whereas an increase of the global kidney cancer death rate was observed.

Towards treating all stages of gastric cancer and gastroesophageal junction adenocarcinoma

Gastric and esophagus cancers were the fifth and the seventh most frequently diagnosed cancers worldwide in 2020, respectively. In the same year, these cancers ranked fourth and sixth in mortality, respectively. Most patients with gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJA) present with inoperable or metastatic disease at the time of diagnosis; resulting in a strong need for efficient and tolerable first-line (1L) and second-line (2L) treatments.

Update on the treatment for advanced HCC

With more than 900,000 newly diagnosed cases in 2020, hepatocellular carcinoma (HCC) is the sixth most frequent malignant disease with a high mortality rate of approximately 92 %. Current first-line treatment for advanced HCC includes atezolizumab plus bevacizumab, as well as the tyrosine kinase inhibitors (TKIs) sorafenib and lenvatinib.

New clinical insights in head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) was the sixth most common cancer in 2018, with more than 700,000 newly diagnosed cases per year and 350,000 cancer deaths worldwide. Around 90 % of head and neck cancers are HNSCC, with oral cavity, oropharynx, hypopharynx, and larynx being the most commonly affected ­areas.

Preface – ESMO Solid Tumor 2022

At the ESMO congress held in Paris, France, and virtually from 9th – 13th September 2022, practice-changing data and high-quality education attracted more than 29,300 participants from over 150 countries.